Klinicheskiy opyt primeneniya preparata Meksidol dlya korrektsii astenovegetativnykh narusheniy u patsientov, perenesshikh legkuyu cherepno-mozgovuyu travmu

The study including 34 patients evaluated the effectiveness of Mexidol for the correction asthenovegetative disturbances in patients with mild traumatic brain injury (MTBI) and cerebral commotion. The use of Mexidol in the complex treatment of these disorders has improved outcomes compared with patients of control group who did not receive Mexidol. It was noted that the use of the drug is preferred at earlier stage of injury. Pronounced therapeutic effect was observed when applying tableted form of Mexidol at a daily dose of 375 mg for 28-30 days in the acute and intermediate stage of MTBI. There were no side effects and complications during therapy in both groups of patients. It is concluded that Mexidol can be used in treatment of MTBI, cerebral commotion, and for the correction of postcommotion syndrome.

brain injury, cerebral commotion, asthenovegetative disturbances, Mexidol